{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T03:46:40Z","timestamp":1788580000042,"version":"build-2803163510"},"reference-count":61,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T00:00:00Z","timestamp":1767571200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Trisomy 21 increases the risk of severe outcomes and mortality in hospitalized individuals with Down syndrome (DS) following SARS-CoV-2 infection. Using data from the Brazilian Epidemiological Surveillance Information System Influenza (SIVEP-Gripe), we analyzed 102,767 hospitalized COVID-19 patients (1,115 DS and 101,652 non-DS, NDS). DS patients had a higher prevalence of comorbidities and required ventilatory support, ICU admission, and intubation more frequently than NDS patients (p\u2009&lt;\u20090.001). Mortality was 4.5 times higher in DS patients aged 0\u201330 years (26.3% vs. 5.9%, p\u2009&lt;\u20090.001) and remained 2.22 times higher after adjusting for comorbidities. DS patients over 30 years also exhibited a 22% increase in mortality (PR 1.22, p\u2009&lt;\u20090.001). Gene expression analysis of pre-pandemic monocytes and T cells from DS individuals revealed upregulated pathways linked to SARS-CoV-2 infection, including interferon signaling and cytokine interactions. This baseline immune dysregulation may contribute to severe COVID-19 outcomes in DS patients. Identifying these altered pathways could inform targeted therapeutic strategies to improve immune homeostasis and clinical outcomes. To the best of our knowledge, this is the first study integrating nationwide clinical outcomes with pre-pandemic immune transcriptomic data to mechanistically explain the heightened COVID-19 severity in individuals with DS.<\/jats:p>","DOI":"10.1371\/journal.pone.0338519","type":"journal-article","created":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T18:59:16Z","timestamp":1767639556000},"page":"e0338519","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Elevated mortality and upregulated SARS-CoV-2-associated pathways in innate and adaptive immune cells from individuals with Down syndrome"],"prefix":"10.1371","volume":"21","author":[{"given":"Daniella Balduino","family":"Victorino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jackeline Moraes","family":"Malheiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Ten-Caten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor Hugo","family":"Cardoso Betta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe Farinha Saad","family":"Barbosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khader","family":"Ghneim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda Caroline","family":"Coirada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda Romano","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuliana Xavier","family":"de Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassia","family":"Silveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Gavegnano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Balderas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana Claudia","family":"Brandao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helder","family":"Nakaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela A.","family":"Wagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciene","family":"Covolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3127-3138","authenticated-orcid":true,"given":"Susan","family":"Pereira Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,1,5]]},"reference":[{"issue":"12","key":"pone.0338519.ref001","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1002\/bdra.20735","article-title":"Updated National Birth Prevalence estimates for selected birth defects in the United States, 2004-2006","volume":"88","author":"SE Parker","year":"2010","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"issue":"4","key":"pone.0338519.ref002","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/gim.2016.127","article-title":"Estimation of the number of people with Down syndrome in the United States","volume":"19","author":"G de Graaf","year":"2017","journal-title":"Genet Med"},{"key":"pone.0338519.ref003","first-page":"82","article-title":"Down syndrome from epidemiologic point of view","author":"M Al-Biltagi","year":"2015","journal-title":"ECPE"},{"issue":"12","key":"pone.0338519.ref004","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nrd2422","article-title":"Interferons at age 50: past, current and future impact on biomedicine","volume":"6","author":"EC Borden","year":"2007","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"pone.0338519.ref005","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/hdy.2010.54","article-title":"Epigenetics and gene expression","volume":"105","author":"ER Gibney","year":"2010","journal-title":"Heredity (Edinb)"},{"issue":"10","key":"pone.0338519.ref006","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41577-020-00429-3","article-title":"The type I interferon response in COVID-19: implications for treatment","volume":"20","author":"JS Lee","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"pone.0338519.ref007","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41436-020-01004-w","article-title":"Individuals with Down syndrome hospitalized with COVID-19 have more severe disease","volume":"23","author":"L Malle","year":"2021","journal-title":"Genet Med"},{"key":"pone.0338519.ref008","doi-asserted-by":"crossref","first-page":"100769","DOI":"10.1016\/j.eclinm.2021.100769","article-title":"Medical vulnerability of individuals with Down syndrome to severe COVID-19-data from the Trisomy 21 Research Society and the UK ISARIC4C survey","volume":"33","author":"A H\u00fcls","year":"2021","journal-title":"EClinicalMedicine"},{"key":"pone.0338519.ref009","doi-asserted-by":"crossref","first-page":"05035","DOI":"10.7189\/jogh.12.05035","article-title":"Differences in clinical presentation, severity, and treatment of COVID-19 among individuals with Down syndrome from India and high-income countries: data from the Trisomy 21 Research Society survey","volume":"12","author":"H Pinku","year":"2022","journal-title":"J Glob Health"},{"key":"pone.0338519.ref010","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.16220","article-title":"Trisomy 21 consistently activates the interferon response","volume":"5","author":"KD Sullivan","year":"2016","journal-title":"Elife"},{"key":"pone.0338519.ref011","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkw377","article-title":"Enrichr: a comprehensive gene set enrichment analysis web server 2016 update","volume":"44","author":"MV Kuleshov","year":"2016","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"pone.0338519.ref012","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1038\/s41598-021-81451-w","article-title":"Network analysis of Down syndrome and SARS-CoV-2 identifies risk and protective factors for COVID-19","volume":"11","author":"I De Toma","year":"2021","journal-title":"Sci Rep"},{"issue":"9","key":"pone.0338519.ref013","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/s41577-018-0029-z","article-title":"IFN\u03b3: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy","volume":"18","author":"LB Ivashkiv","year":"2018","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"pone.0338519.ref014","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1038\/s41577-021-00633-9","article-title":"The type I interferonopathies: 10 years on","volume":"22","author":"YJ Crow","year":"2022","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"pone.0338519.ref015","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1007\/s10875-020-00803-9","article-title":"Three copies of four interferon receptor genes underlie a mild type I interferonopathy in Down syndrome","volume":"40","author":"X-F Kong","year":"2020","journal-title":"J Clin Immunol"},{"key":"pone.0338519.ref016","doi-asserted-by":"crossref","first-page":"5187","DOI":"10.2147\/JIR.S280953","article-title":"Interferon-driven immune dysregulation in Down syndrome: a review of the evidence","volume":"14","author":"H Chung","year":"2021","journal-title":"J Inflamm Res"},{"issue":"7","key":"pone.0338519.ref017","doi-asserted-by":"crossref","first-page":"108407","DOI":"10.1016\/j.celrep.2020.108407","article-title":"JAK1 inhibition blocks lethal immune hypersensitivity in a mouse model of Down syndrome","volume":"33","author":"KD Tuttle","year":"2020","journal-title":"Cell Rep"},{"issue":"48","key":"pone.0338519.ref018","doi-asserted-by":"crossref","first-page":"24231","DOI":"10.1073\/pnas.1908129116","article-title":"Trisomy 21 dysregulates T cell lineages toward an autoimmunity-prone state associated with interferon hyperactivity","volume":"116","author":"P Araya","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"pone.0338519.ref019","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2019.10.038","article-title":"Mass cytometry reveals global immune remodeling with multi-lineage hypersensitivity to type I interferon in Down syndrome","volume":"29","author":"KA Waugh","year":"2019","journal-title":"Cell Rep"},{"issue":"3","key":"pone.0338519.ref020","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1093\/rheumatology\/keab673","article-title":"Interfering with interferons: targeting the JAK-STAT pathway in complications of systemic juvenile idiopathic arthritis (SJIA)","volume":"61","author":"EL Verweyen","year":"2022","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"pone.0338519.ref021","doi-asserted-by":"crossref","first-page":"14818","DOI":"10.1038\/s41598-017-13858-3","article-title":"Trisomy 21 causes changes in the circulating proteome indicative of chronic autoinflammation","volume":"7","author":"KD Sullivan","year":"2017","journal-title":"Sci Rep"},{"issue":"48","key":"pone.0338519.ref022","doi-asserted-by":"crossref","first-page":"84489","DOI":"10.18632\/oncotarget.21060","article-title":"Aberrations in circulating inflammatory cytokine levels in patients with Down syndrome: a meta-analysis","volume":"8","author":"Y Zhang","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"pone.0338519.ref023","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/s41584-020-0377-5","article-title":"Moving towards a systems-based classification of innate immune-mediated diseases","volume":"16","author":"S Savic","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"pone.0338519.ref024","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"DM Schwartz","year":"2016","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"pone.0338519.ref025","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","article-title":"The trinity of COVID-19: immunity, inflammation and intervention","volume":"20","author":"MZ Tay","year":"2020","journal-title":"Nat Rev Immunol"},{"issue":"6","key":"pone.0338519.ref026","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.08.001","article-title":"Severe COVID-19 is marked by a dysregulated myeloid cell compartment","volume":"182","author":"J Schulte-Schrepping","year":"2020","journal-title":"Cell"},{"issue":"7","key":"pone.0338519.ref027","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41577-022-00745-w","article-title":"COVID-19 and Down syndrome: the spark in the fuel","volume":"22","author":"M Majithia","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"pone.0338519.ref028","doi-asserted-by":"crossref","first-page":"4068734","DOI":"10.1155\/2019\/4068734","article-title":"Altered toll-like receptor signalling in children with Down syndrome","volume":"2019","author":"D Huggard","year":"2019","journal-title":"Mediators Inflamm"},{"key":"pone.0338519.ref029","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3389\/fimmu.2019.00447","article-title":"Thymic epithelium abnormalities in DiGeorge and Down syndrome patients contribute to dysregulation in T cell development","volume":"10","author":"GE Marcovecchio","year":"2019","journal-title":"Front Immunol"},{"issue":"8","key":"pone.0338519.ref030","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1111\/j.1651-2227.2012.02696.x","article-title":"Frequency of lower respiratory tract infections in relation to adaptive immunity in children with Down syndrome compared to their healthy siblings","volume":"101","author":"CJM Broers","year":"2012","journal-title":"Acta Paediatr"},{"issue":"11","key":"pone.0338519.ref031","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.micinf.2010.05.007","article-title":"Increased risk of respiratory tract infections in children with Down syndrome: the consequence of an altered immune system","volume":"12","author":"BLP Bloemers","year":"2010","journal-title":"Microbes Infect"},{"issue":"2","key":"pone.0338519.ref032","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1352\/2009.114.100-109","article-title":"T lymphocyte maturation is impaired in healthy young individuals carrying trisomy 21 (Down syndrome)","volume":"114","author":"L Guazzarotti","year":"2009","journal-title":"Am J Intellect Dev Disabil"},{"key":"pone.0338519.ref033","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3389\/fimmu.2020.00827","article-title":"Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19)","volume":"11","author":"B Diao","year":"2020","journal-title":"Front Immunol"},{"issue":"10223","key":"pone.0338519.ref034","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"C Huang","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"pone.0338519.ref035","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1001\/jama.2020.1585","article-title":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","volume":"323","author":"D Wang","year":"2020","journal-title":"JAMA"},{"issue":"4","key":"pone.0338519.ref036","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.21037\/apm-20-2134","article-title":"Dynamic changes in serum IL-6, IL-8, and IL-10 predict the outcome of ICU patients with severe COVID-19","volume":"10","author":"J Li","year":"2021","journal-title":"Ann Palliat Med"},{"issue":"5","key":"pone.0338519.ref037","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00281-020-00804-1","article-title":"Down syndrome, accelerated aging and immunosenescence","volume":"42","author":"N Gensous","year":"2020","journal-title":"Semin Immunopathol"},{"key":"pone.0338519.ref038","doi-asserted-by":"crossref","first-page":"198018","DOI":"10.1016\/j.virusres.2020.198018","article-title":"Gut microbiota and Covid-19- possible link and implications","volume":"285","author":"D Dhar","year":"2020","journal-title":"Virus Res"},{"issue":"5","key":"pone.0338519.ref039","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1038\/s41423-020-0401-3","article-title":"Elevated exhaustion levels and reduced functional diversity of T cells in peripheral blood may predict severe progression in COVID-19 patients","volume":"17","author":"H-Y Zheng","year":"2020","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"pone.0338519.ref040","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1038\/s41467-020-17292-4","article-title":"Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia","volume":"11","author":"S De Biasi","year":"2020","journal-title":"Nat Commun"},{"issue":"4","key":"pone.0338519.ref041","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1038\/s41590-022-01152-y","article-title":"Type I interferon transcriptional network regulates expression of coinhibitory receptors in human T cells","volume":"23","author":"TS Sumida","year":"2022","journal-title":"Nat Immunol"},{"issue":"9","key":"pone.0338519.ref042","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1158\/2326-6066.CIR-16-0193","article-title":"Regulatory T cells: differentiation and function","volume":"4","author":"G Plitas","year":"2016","journal-title":"Cancer Immunol Res"},{"issue":"37","key":"pone.0338519.ref043","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2111315118","article-title":"Profound Treg perturbations correlate with COVID-19 severity","volume":"118","author":"S Galv\u00e1n-Pe\u00f1a","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"31","key":"pone.0338519.ref044","doi-asserted-by":"crossref","first-page":"5040","DOI":"10.1016\/j.vaccine.2011.04.060","article-title":"Immune evaluation and vaccine responses in Down syndrome: evidence of immunodeficiency?","volume":"29","author":"AY Joshi","year":"2011","journal-title":"Vaccine"},{"issue":"7","key":"pone.0338519.ref045","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1016\/j.mayocp.2020.01.039","article-title":"Efficacy and safety of tofacitinib, baricitinib, and upadacitinib for rheumatoid arthritis: a systematic review and meta-analysis","volume":"95","author":"F Wang","year":"2020","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"pone.0338519.ref046","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006740","article-title":"Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors","volume":"13","author":"C Gavegnano","year":"2017","journal-title":"PLoS Pathog"},{"issue":"1","key":"pone.0338519.ref047","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1093\/cid\/ciab212","article-title":"Randomized trial of ruxolitinib in antiretroviral-treated adults with human immunodeficiency virus","volume":"74","author":"VC Marconi","year":"2022","journal-title":"Clin Infect Dis"},{"key":"pone.0338519.ref048","doi-asserted-by":"crossref","DOI":"10.1101\/2022.03.02.22271623","article-title":"Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis","author":"RECOVERY Collaborative Group","year":"2022"},{"issue":"12","key":"pone.0338519.ref049","doi-asserted-by":"crossref","first-page":"6409","DOI":"10.1172\/JCI141772","article-title":"Baricitinib restrains the immune dysregulation in patients with severe COVID-19","volume":"130","author":"V Bronte","year":"2020","journal-title":"J Clin Invest"},{"key":"pone.0338519.ref050","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","author":"AR Marconi","year":"2021","journal-title":"Lancet Respir Dis"},{"issue":"7","key":"pone.0338519.ref051","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s10875-021-01078-4","article-title":"Atypical inflammatory syndrome triggered by SARS-CoV-2 in infants with Down syndrome","volume":"41","author":"L Malle","year":"2021","journal-title":"J Clin Immunol"},{"issue":"11","key":"pone.0338519.ref052","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1016\/j.immuni.2022.10.011","article-title":"Interferons in Down syndrome: when more is less","volume":"55","author":"LD Notarangelo","year":"2022","journal-title":"Immunity"},{"issue":"7898","key":"pone.0338519.ref053","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41586-021-04385-3","article-title":"Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies","volume":"602","author":"Y Cao","year":"2022","journal-title":"Nature"},{"key":"pone.0338519.ref054","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.61312","article-title":"Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants","volume":"9","author":"Y Weisblum","year":"2020","journal-title":"Elife"},{"issue":"7855","key":"pone.0338519.ref055","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41586-021-03324-6","article-title":"mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants","volume":"592","author":"Z Wang","year":"2021","journal-title":"Nature"},{"issue":"62","key":"pone.0338519.ref056","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.abl4340","article-title":"Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths","volume":"6","author":"P Bastard","year":"2021","journal-title":"Sci Immunol"},{"issue":"6","key":"pone.0338519.ref057","article-title":"Life-threatening viral disease in a novel form of autosomal recessive IFNAR2 deficiency in the Arctic","volume":"219","author":"CJA Duncan","year":"2022","journal-title":"J Exp Med"},{"issue":"9","key":"pone.0338519.ref058","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1038\/s41591-021-01433-3","article-title":"Long COVID in a prospective cohort of home-isolated patients","volume":"27","author":"B Blomberg","year":"2021","journal-title":"Nat Med"},{"issue":"5","key":"pone.0338519.ref059","article-title":"Multiple early factors anticipate post-acute COVID-19 sequelae","volume":"185","author":"Y Su","year":"2022","journal-title":"Cell"},{"issue":"1","key":"pone.0338519.ref060","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/s41467-021-27797-1","article-title":"Immunoglobulin signature predicts risk of post-acute COVID-19 syndrome","volume":"13","author":"C Cervia","year":"2022","journal-title":"Nat Commun"},{"issue":"4","key":"pone.0338519.ref061","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1038\/s41591-021-01292-y","article-title":"Attributes and predictors of long COVID","volume":"27","author":"CH Sudre","year":"2021","journal-title":"Nat Med"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0338519","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T18:59:26Z","timestamp":1767639566000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0338519"}},"subtitle":[],"editor":[{"given":"Vinay","family":"Kumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,1,5]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,5]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0338519","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,5]]}}}